Start here if you're new
what it is
Novo Nordisk sells diabetes drugs, weight-loss treatments, and a smaller set of rare-disease and hormone therapies.
how it gets paid
Last year Nvo made $47.5B in revenue. North America was the main engine at $29.4B, or 63% of sales.
what just happened
Novo posted $0.97 in EPS versus a $0.70 estimate, a 38.57% beat.
At a glance
A+ balance sheet — rock-solid finances — built to survive anything
90/100 earnings predictability — you can trust these numbers
15.6x trailing p/e — the market's not buying it — or you found a deal
4.9% dividend yield — cash in your pocket every quarter
26.2% return on capital — every dollar works hard here
xvary composite: 71/100 — average
What they do
Novo Nordisk sells diabetes drugs, weight-loss treatments, and a smaller set of rare-disease and hormone therapies.
Novo wins because it already sits where the demand is. It holds 34% of the global diabetes care market, and 63% of 2024 sales came from North America, where scale in supply, rebates, and doctor access matters. If you are smaller, you spend more just to get in the room.
How they make money
$47.5B
annual revenue
North America
$29.4B
EMEA
$8.4B
China
$4.2B
Rest of world
$4.7B
The products that matter
obesity and diabetes therapies
Wegovy / Ozempic (semaglutide)
inside the $38.0B core franchise
This is the franchise that made the story, and it sits inside the $38.0B obesity and diabetes bucket. The issue now is not demand. It is price, competition, and whether a 62% share gain from two years ago proves repeatable.
core earnings engine
hemophilia pipeline candidate
Mim8
2026 data matters
There is no revenue number attached here yet, which is the point. If 2026 readouts work, Novo gets a growth story beyond semaglutide. If they do not, the business leans even harder on a franchise already under pricing pressure.
second-act test
next-generation obesity candidate
UBT251
2026 readout watch
This is part of the answer to the obvious question: what comes after the current obesity winners. With the stock down 22% in a month, the market is saying future pipeline value needs proof, not adjectives.
pipeline optionality
Key numbers
46.0%
operating margin
Operating margin → the share of sales left after running the business → so what: Novo keeps $0.46 from each $1 before interest and taxes.
$63B
2028 revenue
The fiscal 2028 revenue estimate is $63B versus $46.7B TTM, which is about a 35% jump if Novo executes through the current reset.
4.9%
dividend yield
Dividend yield → cash paid to you relative to the stock price → so what: you are being paid while you wait for sentiment to recover.
26.2%
return on capital
Return on capital → profit earned on the money invested in the business → so what: Novo is still producing elite economics despite the drawdown.
Financial health
A+
strength
- balance sheet grade A+ — near the highest rating possible
- risk rank 3 — safer than 50% of stocks
- price stability 45 / 100
- long-term debt $13.9B (6% of capital)
- net profit margin 30.6% — keeps 31 cents of every dollar in revenue
- return on equity 34% — $0.34 profit for every $1 investors have put in
A+ with balance sheet grade and net profit margin standing out. your money faces less risk here than at most public companies.
Total return vs. market
You invested $10,000 in NVO 3 years ago → it's now worth $7,810.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
Novo posted $0.97 in EPS versus a $0.70 estimate, a 38.57% beat.
The number says the business is still throwing punches. The stock problem is not current profitability. It is whether competition cuts into the future hard enough to keep estimates falling.
$0.97
reported eps
$0.70
est. eps
38.57%
surprise
the number that mattered
The 38.57% EPS beat matters because it shows operations are still strong even after the stock's 62% collapse shifted the market's attention to competition.
-
competition continues to pressure novo nordisk.in mid-20204, novo's ozempic and wegovy drugs, brand names for semaglutide, dominated the very large and rapidly growing groups of those seeking to lose weight and/or control diabetes.
-
the prospects led to a three-fold rise in novo shares over the prior two years.
-
the shares' 62% plunge over the following year was largely due to a dramatic increase in competitive treatments, as well as to generic copycats.
-
and, despite some legal debate, it appears that the competition is to stay.
-
this has not only resulted in cuts into novo's market share, but has also in significant price declines, and is thus compounding the impacts on reported revenues.
source: Yahoo Finance consensus data, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The top threat is an obesity-drug pricing reset in semaglutide. That is already visible in the cut -5% to -13% sales outlook and the move from 84.7% to 81.0% gross margin.
med
obesity-drug price war
The core franchise is still massive, but price pressure is no longer theoretical. Guidance for 2026 moved to -5% to -13%, and margin already came in lower.
This risk hits the $38.0B obesity and diabetes business first, which is why the whole stock rerated.
med
patent expirations
Management explicitly cited patent expirations alongside competition. That means future revenue pressure is not just about rivals taking share. It is also about protection fading.
A lower-price market plus weaker exclusivity is how a premium pharma multiple becomes a plain one.
med
pipeline handoff risk
Mim8 and UBT251 matter because investors need to see what comes after today's obesity winners. This snapshot does not show revenue for either program yet.
If 2026 readouts disappoint, Novo stays tied to a franchise already fighting on price.
med
currency and regulatory noise
The annual report flags foreign exchange risk, and the page also references FDA warning letters and investor investigations. None of that breaks the business alone, but it adds friction to an already fragile story.
You own the ADR in dollars. The company reports in Danish kroner. That adds one more variable while the market is already repricing the core business.
A 22% monthly drop wiped out roughly $50B, and the stock still sits far closer to the $43 low than the $94 high of its 52-week range. The market is treating these risks as structural until proven otherwise.
source: institutional data · regulatory filings · risk analysis
Pay attention to
margin
gross margin direction
81.0% is still elite. If that number keeps falling from the 84.7% level seen before, the pricing-power thesis keeps weakening.
guidance
2026 sales outlook
The current range is -5% to -13%. If management cuts below that low end, the reset is getting deeper, not cleaner.
pipeline
2026 Mim8 and UBT251 readouts
These are the obvious catalysts for a second growth engine. If the data is good, the story broadens. If not, semaglutide remains the whole argument.
capital return
DKK 15bn buyback follow-through
A buyback during a drawdown is management saying the stock is cheap. You want that signal backed by stabilizing fundamentals, not just financial engineering.
Analyst rankings
earnings predictability
90 / 100
This company has historically been easy to model. In human-speak, analysts usually trust the numbers even when they dislike the direction.
risk rank
3
This is safer than a speculative biotech, but the 45 / 100 price stability score tells you the stock itself is not acting defensive right now.
source: institutional data
Institutional activity
institutions have been net selling for 3 consecutive quarters — 643 buyers vs. 749 sellers in 3q2025. total institutional holdings: 0.3B shares. net selling for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$43
$104
$50
current price
$74
target midpoint · +47% from current · 3-5yr high: $125 (+150% · 28% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive